PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Lobbying for PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.